<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157260</url>
  </required_header>
  <id_info>
    <org_study_id>Ewha AST-120</org_study_id>
    <nct_id>NCT01157260</nct_id>
  </id_info>
  <brief_title>The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease</brief_title>
  <official_title>The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney
      disease (CKD). AST-120 (KremezinÂ®; Kureha Corporation, Tokyo, Japan) removes indole, which is
      the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been
      shown to retard the deterioration of renal function in CKD patients through reducing the
      levels of IS.

      IS was reported to promote aortic calcification and stimulate the proliferation of vascular
      smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With
      this background, the investigators will performed the study whether AST-120 improve the
      endothelial dysfunction in CKD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent
      improve endothelial dysfunction in stage 3,4 chronic kidney disease patients
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of FMD(Flow Mediated Dilatation)</measure>
    <time_frame>6 months</time_frame>
    <description>FMD (Flow Mediated Dilatation): percent change of FMD response to hyperemia and after sublingual nitroglycerin on brachial artery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Indoxyl Sulfate</measure>
    <time_frame>3 months, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>AST-120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AST-120 administration 2g three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Chronic Kidney disease stage 3,4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kremezin</intervention_name>
    <description>AST-120 2g three times a day</description>
    <arm_group_label>AST-120</arm_group_label>
    <other_name>AST-120 (Kremezin) 2g three times a day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Chronic kidney disease (Stage3 - Stage4)

          -  Patients who are able and willing to understand, sign and date an informed consent
             document, and authorize access to protected health information

        Exclusion Criteria:

          -  Acute gastric or duodenal ulcer

          -  Severe constipation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hee Kang, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MINA YU, MD</last_name>
    <phone>+82-2-2650-2562</phone>
    <email>yuelizabeth@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gil-Soon Yang, NR</last_name>
    <phone>+82-2-2650-5132</phone>
    <email>40739@eumc.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mina Yu, MD</last_name>
      <phone>+82-2-2650-2562</phone>
      <email>yuelizabeth@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Gil-Soon Yang, NR</last_name>
      <phone>+82-2-2650-5132</phone>
    </contact_backup>
    <investigator>
      <last_name>Duk-Hee Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nephrology</name_title>
    <organization>Ewha Womans University Mokdong Hospital</organization>
  </responsible_party>
  <keyword>Indoxyl sulfate</keyword>
  <keyword>AST-120</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

